Please Wait
Applying Filters...
menu
    • menu
    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-06-09

    Virtual Booth

    An Enquiry

    Menu

    Tolimidone

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Biodexa Begins Ph 2 Trial of Tolimidone in Type 1 Diabetes
    Biodexa Begins Ph 2 Trial of Tolimidone in Type 1 Diabetes

    04 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/04/3093562/0/en/Biodexa-Announces-Recruitment-of-First-Patient-in-Phase-2-Study-of-Tolimidone-in-Type-1-Diabetes.html

    GLOBENEWSWIRE
    04 Jun 2025
    Share Share
    Biodexa's Phase 2a Study Of Tolimidone For T1D Approved In Canada
    Biodexa's Phase 2a Study Of Tolimidone For T1D Approved In Canada

    16 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/16/2913782/0/en/Biodexa-Announces-Phase-2a-Study-of-Tolimidone-in-Type-1-Diabetes-Approved-by-Health-Canada.html

    GLOBENEWSWIRE
    16 Jul 2024
    Share Share
    Biodexa Enters Into Agreements to Acquire Worldwide License to Tolimidone
    Biodexa Enters Into Agreements to Acquire Worldwide License to Tolimidone

    27 Nov 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/11/27/2786218/0/en/Biodexa-Enters-Into-Agreements-to-Acquire-Exclusive-Worldwide-License-to-Tolimidone-a-Phase-II-Ready-Asset-for-Type-1-Diabetes.html

    GLOBENEWSWIRE
    27 Nov 2023
    Share Share
    Adhera Therapeutics Expands Relationship with Melior Pharmaceuticals I,Adds NASH
    Adhera Therapeutics Expands Relationship with Melior Pharmaceuticals I,Adds NASH

    20 Oct 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/10/20/2317559/0/en/Adhera-Therapeutics-Expands-Relationship-with-Melior-Pharmaceuticals-I-Adds-NASH-and-Pulmonary-Inflammation-to-Portfolio-of-Target-Indications.html

    GLOBENEWSWIRE
    20 Oct 2021
    Share Share
    PerkinElmer Completes Acquisition of Oxford Immunotec Global PLC
    PerkinElmer Completes Acquisition of Oxford Immunotec Global PLC

    09 Mar 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210309005100/en

    BUSINESSWIRE
    09 Mar 2021
    Share Share
    Melior Receives IND Clearance from US FDA for COVID-19 Therapeutic
    Melior Receives IND Clearance from US FDA for COVID-19 Therapeutic

    09 Mar 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210309005144/en

    BUSINESSWIRE
    09 Mar 2021
    Share Share